Acadian Asset Management LLC Argenx Se Transaction History

Acadian Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$369.35 - $548.43 $89,382 - $132,720	242 Added 42.91%	806 $396,000
Q2 2023 Aug 07, 2023	BUY	$360.14 - $422.58 $203,118 - $238,335	564 New	564 $219,000
Q4 2022 Feb 14, 2023	SELL	$342.17 - $402.31 $134,814 - $158,510	-394 Reduced 29.62%	936 $354,000
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $456,456 - $526,347	1,330 New	1,330 $469,000
Q4 2019 Feb 06, 2020	SELL	$106.59 - $164.21 $319 - $492	-3 Closed	0 $0
Q3 2019 Nov 07, 2019	BUY	$113.31 - $150.51 $339 - $451	3 New	3 $0
Q3 2018 Oct 30, 2018	SELL	$75.5 - $96.63 $6,568 - $8,406	-87 Closed	0 $0
Q2 2018 Jul 24, 2018	SELL	$74.84 - $100.16 $138,229 - $184,995	-1,847 Reduced 95.5%	87 $7,000
Q1 2018 Apr 12, 2018	BUY	$56.95 - $85.19 $110,141 - $164,757	1,934 New	1,934 $156,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.